Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8

Prostate

Volumn 31, Issue 2, 1997, Pages 91-97

  Ljung, Gunilla ^a,b,c   Norberg, Mona ^a   Holmberg, Lars ^a   Busch, Christer ^a   Nilsson, Sten ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Malar Hospital   (Sweden)

^c Malar Hospital   (Sweden)

Author keywords

core biopsy; cytokeratin 8; endocrine treatment; PAP; prostatic adenocarcinoma; PSA; radiation therapy

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BIOCHEMICAL MARKER; CYTOKERATIN; ESTROGEN; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CELL STRUCTURE; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROTEIN SYNTHESIS; TUMOR CELL;

ACID PHOSPHATASE; ADENOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; NEOPLASM, RESIDUAL; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030906561     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970501)31:2<91::AID-PROS3>3.0.CO;2-K     Document Type: Article

References (49)

1. Kabalin JN Hodge KK, McNeal JE, Stamey TA: Identification of residual cancer in the prostate following radiation therapy; roles of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 142: 326-331, 1989.
2. Herr HW, Whitmore WF: Significance of prostate biopsies after radiation therapy for carcinoma of the prostate. Prostate 3:339-350, 1982.
3. Ljung G, Norberg M, de la Torre M, Egevad L, Holmberg L, Busch C, Nilsson S: Transrectal ultrasonically-guided core biopsies in the assessment of local cure of prostatic cancer after radical external beam radiotherapy. Acta Oncol 34:945-952, 1995.
4. Ljung G, Egevad L, Norberg M, de la Torre M, Holmberg L, Busch C, Nilsson S: Assessment of proliferation indicators in residual prostatic adenocarcinoma cells after radical external beam radiotherapy. Prostate 29: 303-310, 1996.
5. Mostofi FK, Sesterhehn I, Sobin LH: "Histological Typing of Prostatic Tumours. International Histological Classifications of Tumours." No. 22. Geneva: World Health Organization, 1980.
6. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol 17:159-163, 1979.
7. Brawer MK: Prostate specific antigen. A review. acta Oncol 30:161-168, 1991.
8. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr., Bruzek DJ, Rock RC, Brendler CB, Walsh PC: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 139:766-772, 1988.
9. Stamey TA, Vang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adinocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
10. Hudson MA, Bahnson RB, Catalona WJ: Clinical use of prostate specific antigen in patient with prostate cancer. J Urol 142:1011-1017, 1989.
11. Brawer MK, Nagle RB, Pitts W, Freiha FS, Gamble SL: Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates. Cancer 63:454-460, 1989.
12. Nadji M, Talei SZ, Castro A, Chu TM, Murphy GP, Wang MC, Morales AR: Prostatic-specific antigen: An immunohistologic marker for prostatic neoplasms. Cancer 48:1221-1232, 1981.
13. Lilja H: A kellekrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76:1899-1903, 1985.
14. Abalin RJ: Immunochemical identification of prostatic tissue-specific acid prostate. Clin Chem 19:786-788, 1973.
15. Jöbsis AC, De Vries GP, Anholt RRH: Demonstration of the prostatic origin of metastases: An immunohistochemical method for formalin-fixed embedded tissue. Cancer 41:1788-1793, 1978.
16. Jöbsis AC, De Vries GP, Meijer AEFH, Ploem JS: The immunohistochemical detection of prostatic acid phosphatase: Its possibilities and limitations in tumour histochemistry. Histochem J 13:961-973, 1981.
17. Nadji M, Tabei SZ, Castro A, Chu TM, Morales AR: Prostatic origin of tumors. An immunohistochemical study. Am J Clin Pathol 73:735-739, 1980.
18. Vihko P, Kontturi M, Korhonen K: Purification of human prostatic acid phosphatase by affinity chromatography and isoelectric focusing. Part I. Clin Chem 24: 466-470, 1978.
19. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R: The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumours and cultured cells. Cell 31:11-24, 1982.
20. Quinlan RA, Schiller DL, Hatzfeld M, Achstätter T, Moll R, Jorcano JI, Magin TM, Franke WW: Patterns of expression and organization of cytokeratin intermediate filaments. In Wang E, Fishman D, Liem RRH, Sun TT (eds): "Intermediate Filaments." Ann NY Acad Sci 455:282-306, 1985.
21. Copper D, Schermer A, Sun TT: Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: Strategies, applications and limitations. Lab Invest 52:243-256, 1985.
22. Ramackers FCS, Puts JJG, Moesker O, Kant A, Huysmans A, Haag D, Jap PHK, Herman CJ, Vooijs GP: Antibodies to intermediate filament proteins in the immunohistochemical identification of human tumours: an overview. Histochem J 15:691-713, 1983.
23. Silen Å: "Monoclonal Anti-cytokeratin Antibodies and Cytokeratin Fragments as in vitro and in vivo Tumour Markers." Comprehensive Summaries of Uppsala Dissertions from the Faculty of Medicine 506. Acta Universitatis Upsaliensis, Uppsala, 1994.
24. TNM Classification of Malignant Tumours: UICC, 3rd Ed. Berlin: Springer-Verlag, 1987.
25. Mostofi FK: Grading of prostate carcinoma. Cancer Chemother Rep 59:111-120, 1975.
26. Hsu S-M, Raine L, Fanger H: A comparative study of the peroxidase-antiperoxidase method and an avidinbiotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 75:734-738, 1981.
27. Bourne JA: "Handbook of Immunoperoxidase Staining Methods." DAKO Corp, Santa Barbara, CA, 1983.
28. Busch C, Malmström PU, Norlen BJ, Sällström J, Brodin T, Lundblad A: A grading system for the immunostaining of A, B and H blood group isoantigens in bladder carcinoma. Anticancer Res 8:81-88, 1988.
29. Vernon SE, Williams WD: Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific phosphatase and prostatic specific antigen by immunohistochemistry. J Urol 130:95-98, 1983.
30. Mahan DE, Bruce AW, Manley PN, Franchi L: Immunohistochemical evaluation of prostatic carcinoma before and after radiotherapy. J Urol 124:488-491, 1980.
31. Hakalahti L, Vihko P, Henttu P, Autio-Harmainen H, Soini Y, Vihko R: Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using Northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int J Cancer 55:590-597, 1993.
32. Garde SV, Sheth AR, Venkatestan VM, Panchal CJ, Porter AT, Grignon DJ: Prostate inhibin peptide (PIP) in prostate cancer: A comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). Cancer Lett 78:11-17, 1994.
33. Stege R, Lundh B, Tribukait B, Pousette Å, Carlström K, Hasenson M: Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma. J Urol 144: 299-302, 1990.
34. Vitali A, Ardoino S, Durante P, Ferro MA, Li Causi F, Parodi C, Sanguinetti G, Gaffuri M, Paerachino M, Salvadori RP: Correlation between immunohistochemical patterns and serum levels of PSA and PSAP in prostatic pathology: Evaluation of 198 prostatic fine needle biopsies. Anticancer Res 14:1503-1508, 1994.
35. Svanholm H: Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase. Acta Pathol Microbiol Immunol Scand A 94:7-12, 1986.
36. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991.
37. Epstein J, I. PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin North Am 55:757-770, 1993.
38. Bazinet M, Hamdy SM, Bégin LR, Stephenson RA, Fair WR: Prognostic significance of antigenic heterogeneity, Gleason grade and ploidy of lymph node metastases in patients with prostate cancer. Prostate 20:311-326, 1992.
39. Pretlow TG, Yang B, Kaetzel CS, Delmoro CM, Kamis SM, Bodner DR, Kursh E, Resnick MI, Bradley EL Jr.: Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer 49:645-649, 1991.
40. Abrahamsson PA, Falkmer LS, Wadstrom LB: Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostatic glands. Prostate 12:39-46, 1988.
41. Qiu SD, Young CYF, Bilhartz DL, Prescott JL, Farrow GM, He WW, Tindall DJ: In situ hybridization of prostate specific antigen m RNA in human prostate. J Urol 144:1550-1556, 1990.
42. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino P: Prostate specific antigen and Gleason grade: An immunohistochemical study of prostate cancer. J Urol 151:1558-1564, 1994.
43. Berner A, Nesland JM, Waehre H, Fosså SJ: Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre-and post-treatment specimens. Br J Cancer 68:380-384, 1993.
44. Sakai H, Shiraishi K, Minami Y, Yushita Y, Kanetake H, Saito Y: Immunohistochemical prostatic acid phosphatase level as a prognostic parameter in prostatic carcinoma. Prostate 19:265-272, 1991.
45. Epstein JI, Egglestone JC: Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: Prognostic implications. Hum Pathol 15:853-859, 1984.
46. Berner A, Waere H, Nesland JM, Paus E, Danielsen HE, Fosså SD: DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma. Br J Urol 75:26-32, 1995.
47. Stege R, Tribukait B, Lundh B, Carlström K, Pousette A, Hasenson M: Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J Urol 148:833-837, 1992.
48. Hammond ME, Sause WT, Martz KL, Pilepich NV, Asbell SO, Rubin P, Myers RP, Farrow GM: Correlation of prostate-specific acid phosphatase and prostate-specific antigen immunocytochemistry with survival in prostate carcinoma. Cancer 63:461-466, 1989.
49. de Winter JAR, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkman AO, Santerse AB, Schröder FH, van der Kwast TH: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735-746, 1994.